B+
Bull case
25%
Probability
Target price
$9.00
Analysis reference price unavailable
Analysis 2026-09-30 · RankAlpha Sentiment Codex
DTIL
Precision BioSciencesFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
The reported HBV biomarker findings could gain credibility with larger, durable follow-up data, while DMD dosing adds a second clinical program. Management expects cash to support both programs' data milestones through 2028 [#SEC-8K-2026-08-06] [#8-K-2026-08-24].
Posture
Defensive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta -0.1.
What can break
Cash declined during the first half of 2026; the stated runway partly assumes continued access to an at-the-market facility, creating dilution risk [#SEC-8K-2026-08-06].
Momentum
46
Value
41
Sentiment
41
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $5.80 · Bull $9.00 · Bear $3.00Analysis 2026-09-30; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-23 • Vendor: Data Vendor v1
Scores
As of 2026-10-23 • Model: HYBRID_IC_RP
AI Memo
As of 2026-09-30 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-10-23
Investment thesis
As of 2026-10-23
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-23. Definitions
Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net Neutral
Target $29.40
Why
Momentum46 · Δ7d -2.8
Value41 · Δ7d -0.1
Sentiment41 · Δ7d -14.2
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Confirming evidence
- • Value remains the lead driver in the composite, 7D delta -0.1.
Contradictions & invalidation
- • Cash declined during the first half of 2026; the stated runway partly assumes continued access to an at-the-market facility, creating dilution risk [#SEC-8K-2026-08-06].
- • First-in-human DMD safety, enrollment and subsequent efficacy remain unproven.
- • HBV evidence remains early and based on few patients; DMD has not reported initial safety data.
Catalyst clock
2026-12-31
Year-end PBGENE-HBV clinical update
Lead driver: Value · See fundamentals
Momentum
46
8% active weight
Current posture
7d trendSoftening
Δ7d
-2.8
Δ21d
+18.3
Value
41
47% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
-0.4
Sentiment
41
45% active weight
Current posture
7d trendSoftening
Δ7d
-14.2
Δ21d
-10.9
Why this grade
Composite grade F. Momentum 46.4 / Value 40.6 / Sentiment 41.2
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-09-30. Scenario method
Most likely
B
Base case
45%
Probability
Target price
$5.80
Analysis reference price unavailable
Analysis 2026-09-30 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$3.00
Analysis reference price unavailable
Analysis 2026-09-30 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-10-23
Fundamentals (TTM)
As of 2026-10-23
Market Cap
$183.27M
Beta
1.31
Shares Out
27.6M
P/E (TTM) · Derived
-1.8
P/S (TTM)
133.84
P/FCF (TTM) · Derived
-2.53
Rev YoY
-100.0%
EPS YoY
-40.7%
Gross Margin
+94.2%
Op Margin
-86.8%
Net Debt
-$86.78M
Current Ratio
12.82
As of 2026-10-23 • Updated nightlySource: Internal modelMethods & Data